National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 18252 [2020-06769]
Download as PDF
<![CDATA[
18252
Federal Register / Vol. 85, No. 63 / Wednesday, April 1, 2020 / Notices
MSC 7808, Bethesda, MD 20892, 301–594–
3292, niw@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 26, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: March 27, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–06769 Filed 3–31–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration (SAMHSA)
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
[FR Doc. 2020–06767 Filed 3–31–20; 8:45 am]
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review in compliance with the
Paperwork Reduction Act. To request a
copy of these documents, call the
SAMHSA Reports Clearance Officer at
(240) 276–0361.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Mentored Clinical and Basic Science Review
Committee.
Date: April 24, 2020.
Time: 5:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Keith A. Mintzer, Ph.D.,
Scientific Review Officer, Office of Review
Branch/DERA, National Heart, Lung, and
Blood Institute, 6705 Rockledge Drive,
Bethesda, MD 20892–7924, 301–827–7949,
mintzerk@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
VerDate Sep<11>2014
18:31 Mar 31, 2020
Jkt 250001
Project: Protection and Advocacy for
Individuals With Mental Illness
(PAIMI) Annual Program Performance
Report (OMB No. 0930–0169)—
Extension
The Protection and Advocacy for
Individuals with Mental Illness (PAIMI)
Act at 42 U.S.C. 10801 et seq.,
authorized funds to the same protection
and advocacy (P&A) systems created
under the Developmental Disabilities
Assistance and Bill of Rights Act of
1975, known as the DD Act (as amended
in 2000, 42 U.S.C. 15001 et seq.]. The
DD Act supports the Protection and
Advocacy for Developmental
Disabilities (PADD) Program
administered by the Administration on
Intellectual and Developmental
Disabilities (AIDD) within the
Administration on Community Living.
AIDD is the lead federal P&A agency.
The PAIMI Program supports the same
governor-designated P&A systems
established under the DD Act by
providing legal-based individual and
systemic advocacy services to
individuals with significant (severe)
mental illness (adults) and significant
(severe) emotional impairment
(children/youth) who are at risk for
abuse, neglect and other rights
violations while residing in a care or
treatment facility.
In 2000, the PAIMI Act amendments
created a 57th P&A system—the
American Indian Consortium (the
Navajo and Hopi Tribes in the Four
Corners region of the Southwest). The
Act, at 42 U.S.C. 10804(d), states that a
P&A system may use its allotment to
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
provide representation to individuals
with mental illness, as defined by
section 42 U.S.C. 10802 (4)(B)(iii)
residing in the community, including
their own home, only, if the total
allotment under this title for any fiscal
year is $30 million or more, and in such
cases an eligible P&A system must give
priority to representing PAIMI-eligible
individuals, as defined by 42 U.S.C.
10802(4)(A) and (B)(i).
The Children’s Health Act of 2000
(CHA) also referenced the state P&A
system authority to obtain information
on incidents of seclusion, restraint and
related deaths [see, CHA, Part H at 42
U.S.C. 290ii-1]. PAIMI Program formula
grants awarded by SAMHSA go directly
to each of the 57 governor-designated
P&A systems. These systems are located
in each of the 50 states, the District of
Columbia, the American Indian
Consortium, American Samoa, Guam,
the Commonwealth of the Northern
Mariana Islands, the Commonwealth of
Puerto Rico, and the U.S. Virgin Islands.
The PAIMI Act at 42 U.S.C. 10805(7)
requires that each P&A system prepare
and transmit to the Secretary of The
U.S. Department of Health and Human
Services (HHS), and to the head of its
State mental health agency a report on
January 1. This report describes the
activities, accomplishments, and
expenditures of the system during the
most recently completed fiscal year,
including a section prepared by the
advisory council (the PAIMI Advisory
Council or PAC) that describes the
activities of the council and its
independent assessment of the
operations of the system.
SAMHSA proposes minor revisions to
its annual PAIMI Program Performance
Report (PPR), including the advisory
council section, at this time for the
following reasons: (1) The revisions
revise the PAIMI PPR, as appropriate,
for consistency with the annual
reporting requirements under the PAIMI
Act and Rules [42 CFR part 51]; (2) The
revisions simplify the electronic data
entered by state P&A systems; (3)
SAMHSA will reduce wherever feasible
the current reporting burden by
removing any information that does not
facilitate evaluation of the programmatic
and fiscal effectiveness of a state P&A
system; (4) The updated electronic
version will expedite SAMHSA’s ability
to prepare the biennial report; (5) The
updated electronic version will improve
SAMHSA’s ability to generate reports,
analyze trends and more expeditiously
provide feedback to PAIMI programs.
This PPR/ACR will be effective for the
FY 2021 PPR reports due on January 1,
2022.
E:\FR\FM\01APN1.SGM
01APN1
]]>Agencies
[Federal Register Volume 85, Number 63 (Wednesday, April 1, 2020)]
[Notices]
[Page 18252]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06769]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Mentored Clinical and Basic Science Review
Committee.
Date: April 24, 2020.
Time: 5:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6705 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Keith A. Mintzer, Ph.D., Scientific Review
Officer, Office of Review Branch/DERA, National Heart, Lung, and
Blood Institute, 6705 Rockledge Drive, Bethesda, MD 20892-7924, 301-
827-7949, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: March 27, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-06769 Filed 3-31-20; 8:45 am]
BILLING CODE 4140-01-P
